UNLABELLED: The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. MATERIALS AND METHODS: We investigated 119 breast cancer patients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). RESULTS: Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. CONCLUSION: There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancer patients.
UNLABELLED: The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer. MATERIALS AND METHODS: We investigated 119 breast cancerpatients who had metachronous metastases. We evaluated levels of CEA and CA 15-3 at the time of first recurrence and at every further disease progression (PD). RESULTS: Increasing value levels of CEA as well as CA 15-3 were found in correlation to the number of PD with a continuously increasing sensitivity in the detection of metastatic disease for each marker alone and especially in combination. At the first time of distant metastasis, CEA and CA 15-3 were above the 95th percentile of healthy individuals in 53.5% and 71.8%, respectively. During disease progression the sensitivities were: 1st PD for CEA/ CA 15-3 54.1%/ 70.6%, 2nd PD 63.5%/ 81.2% and 3rd PD 68.6%/ 90%. CONCLUSION: There is a correlation between elevation of CEA and/or CA 15-3 and disease progression, in breast cancerpatients.
Authors: Y Touchefeu; C Bailly; E Frampas; T Eugène; C Rousseau; M Bourgeois; C Bossard; A Faivre-Chauvet; A Rauscher; D Masson; A David; E Cerato; T Carlier; R M Sharkey; D M Goldenberg; J Barbet; F Kraeber-Bodere; C Bodet-Milin Journal: Eur J Nucl Med Mol Imaging Date: 2020-08-21 Impact factor: 9.236
Authors: Laura L Travaini; Giuseppe Trifirò; Laura Ravasi; Lorenzo Monfardini; Paolo Della Vigna; Guido Bonomo; Antonio Chiappa; Andrew Mallia; Mahila Ferrari; Franco Orsi; Giovanni Paganelli Journal: Eur J Nucl Med Mol Imaging Date: 2008-03-13 Impact factor: 9.236
Authors: Oliver J Stoetzer; Debora M I Fersching; Christoph Salat; Oliver Steinkohl; Christian J Gabka; Ulrich Hamann; Michael Braun; Axel-Mario Feller; Volker Heinemann; Barbara Siegele; Dorothea Nagel; Stefan Holdenrieder Journal: Tumour Biol Date: 2012-09-15
Authors: Elisabetta Manuali; Antonio De Giuseppe; Francesco Feliziani; Katia Forti; Cristina Casciari; Maria Chiara Marchesi; Eugenio Pacifico; Karol M Pawłowski; Kinga Majchrzak; Magdalena Król Journal: BMC Vet Res Date: 2012-06-22 Impact factor: 2.741